natgillin/translations-raw huggingface dataset:
- The used capsule should be removed from the Inbrija inhaler and the second capsule loaded into the inhaler. 
- Iskorištenu kapsulu potrebno je ukloniti iz Inbrija inhalatora i u inhalator umetnuti novu kapsulu.
Delusion 
deluzija
Because of the risk of bronchospasm, use of levodopa inhalation powder in patients with asthma, chronic obstructive pulmonary disease (COPD), or other chronic underlying lung disease is not recommended. 
Zbog rizika za nastanak bronhospazma, ne preporučuje se primjena levodope u obliku praška za inhaliranje u bolesnika s astmom, kroničnom opstruktivnom plućnom bolesti (KOPB) ili drugim podležećim kroničnim plućnim bolestima.
Attach the mouthpiece to the handle by pushing until you hear a click. 
Usnik pričvrstite tako da ga pritišćete na držak dok ne začujete škljocaj.
A full dose is 2 capsules. 
Puna doza iznosi 2 kapsule.
Talk to your doctor or pharmacist if you develop any of the symptoms below whilst using Inbrija: - sudden sleep attacks or sometimes feeling very sleepy; - changes in or worsening of your mental state, which may be severe such as psychotic and suicidal behaviour; - hallucinations, along with being confused, unable to sleep and excessive dreaming. 
Obratite se svom liječniku ili ljekarniku ako se kod Vas, dok uzimate Inbriju, pojave neki od sljedećih simptoma: - iznenadni napadaji spavanja ili se ponekad osjećate jako pospani - promjene ili pogoršanje mentalnog stanja, koje može biti teško poput psihotičnog ili suicidalnog ponašanja
Driving and using machines Inbrija can cause excessive drowsiness, dizziness and sudden sleep attacks. 
Inbrija može uzrokovati prekomjernu omamljenost, omaglicu i iznenadne napadaje spavanja.
A clinical study was performed with Inbrija 66 mg (2 x 33 mg capsules) in 24 healthy subjects (13 men and 11 women). 
Kliničko ispitivanje primjene Inbrije u dozi od 66 mg (2 kapsule od 33 mg) provedeno je na 24 zdrava ispitanika (13 muškaraca i 11 žena).
Carton containing 60 hard capsules (15 blister strips) and one inhaler. 
Kutija sadrži 60 tvrdih kapsula (15 blistera) i jedan inhalator.
• You should inhale the contents of the second capsule within 10 minutes of the first one. 
• Sadržaj druge kapsule morate udahnuti unutar 10 minuta nakon prve kapsule.
Contains colfosceril palmitate (DPPC), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, maize starch, shellac, black iron oxide (E 172), propylene glycol, potassium hydroxide. 
Sadrži kolfoscerilpalmitat (DPPC), natrijev klorid, hipromelozu, titanijev dioksid (E 171), karagenan, kalijev klorid, karnauba vosak, kukuruzni škrob, šelak, crni željezov oksid (E 172), propilenglikol,
Adverse reactions reported with oral levodopa 
Nuspojave prijavljene s peroralnom levodopom
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava anemija,
Psychotic disorder, Impulse-control disorder (see section 4.4), 
psihotični poremećaji, poremećaj kontrole nagona (vidjeti dio 4.4),
Use one capsule at a time. 
Kapsule primijenite jednu po jednu.
- The medicine must be used only with the Inbrija inhaler device. 
- Ovaj lijek se smije primijeniti samo pomoću Inbrija inhalatora.
You should inhale the contents of the second capsule within 10 minutes of the first one. 
Sadržaj druge kapsule morate udahnuti unutar 10 minuta nakon prve kapsule.
Breast-feeding should be discontinued during treatment with Inbrija. 
Dojenje treba prekinuti za vrijeme liječenja lijekom Inbrija.
- The other ingredients comprising the powder and capsule are colfosceril palmitate (DPPC), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, maize starch, shellac, black iron oxide (E 172), propylene glycol and potassium hydroxide. 
- Drugi sastojci praška i kapsule su kolfoscerilpalmitat (DPPC) natrijev klorid, hipromeloza, titanijev dioksid (E 171), karagenan, kalijev klorid, karnauba vosak, kukuruzni škrob, šelak, crni željezov oksid (E 172), propilenglikol i kalijev hidroksid.
Thrombophlebitis, Hot flush 
tromboflebitis, navale vrućine
A summary of how to use Inbrija is provided below. 
Sažetak kako primjenjivati Inbriju nalazi se u nastavku.
- a carton containing 60 hard capsules (15 blister strips) and one inhaler - a carton containing 92 hard capsules (23 blister strips) and one inhaler 
Veličine pakiranja su - kutija sa 60 tvrdih kapsula (15 blistera) i jedan inhalator - kutija sa 92 tvrde kapsule (23 blistera) i jedan inhalator
You should hear the capsule “whirl”. 
Trebate čuti da se kapsula „zavrtjela“.
Vision blurred, Diplopia, Mydriasis, Oculogyric crisis, Blepharospasm 
midrijaza, okulogirična kriza, blefarospazam
Bacterial test positive, Weight decreased, 
pozitivni test na prisutnost bakterija,
Dispose and store Step 12: Dispose of used capsules 
Odlaganje i čuvanje 12. korak: Odlaganje iskorištenih kapsula Iskorištene kapsule zbrinite u skladu s nacionalnim propisima.
Selective Monoamine Oxidase (MAO) inhibitors 
Selektivni inhibitori monoaminooksidaze (MAO)
- blurred vision; double vision; widening pupil; prolonged rolling eyes upwards; involuntary tight closure of the eyelids; - heart problems, a noticeably rapid, strong, or irregular heartbeat; - low blood pressure soon after standing up; high blood pressure; fainting; blood clot in a vein; hot flushes; - shortness of breath; difficulty in breathing; difficulty in speaking; hiccups; - stomach pains; constipation; diarrhoea; dry mouth; stomach and intestinal bleeding; stomach ulcer; difficulty in swallowing; indigestion; burning sensation in the mouth; passing wind; change in colour of saliva; more saliva than normal; - swelling of face, lips, tongue, limbs and genitals; excessive sweating; rash; severe itching of the skin; condition called Henoch-Schoenlein purpura, the symptoms of which include a purple spotted skin rash; allergic reaction causing a rash of round, red welts on the skin that itch intensely; hair loss; discoloured sweat; - muscle spasms; lockjaw; - difficulty in emptying the bladder; abnormal urine colour; loss of bladder control; - painful, abnormally long-lasting erection; - swelling of lower legs or hands; feeling weak and having no energy; feeling tired; lack of energy; difficulty in walking; chest pain; - abnormal blood investigation results; weight loss; weight gain. 
- poremećaji pokreta pri čemu se mišići osobe nekontrolirano kontrahiraju; iznenadne, ponekad nepredvidive promjene simptoma zbog povratka simptoma Parkinsonove bolesti; pospanost; omaglica; pogoršanje Parkinsonove bolesti; osjećaj trnaca i bockanja; glavobolja, nevoljno drhtanje; napadaji; iznenadno padanje u san; sindrom nemirnih nogu; ataksija (poremećaj koji utječe na koordinaciju pokreta, ravnotežu i govor); poremećen osjet okusa; poremećaji mentalnog stanja koji zahvaćaju sposobnost učenja, pamćenja, opažanja i rješavanja problema; Hornerov sindrom (poremećaj oka); demencija - zamućen vid; dvoslike; proširenje zjenica; dugotrajno okretanje očiju prema gore; nevoljno čvrsto stiskanje vjeđa - srčani problemi, osjetno brzi, snažni ili nepravilni otkucaji srca - niski krvni tlak odmah nakon ustajanja u uspravni položaj; visoki krvi tlak; nesvjestica; krvni ugrušak u veni; navale vrućine - nedostatak zraka; otežano disanje; otežani govor; štucanje - bol u želucu; zatvor; proljev; suha usta; krvarenje iz želuca ili crijeva; čir na želucu; otežano gutanje; probavne tegobe; osjećaj pečenja u ustima; vjetrovi; promjena boje sline; obilnije stvaranje sline nego je to normalno
The pharmacokinetics of Inbrija 66 mg (2 x 33 mg capsules) and carbidopa/levodopa 25 mg/100 mg immediate release tablets was evaluated in 24 healthy volunteers in a fasted state receiving a total of 50 mg carbidopa every 8 hours. 
Farmakokinetika Inbrije u dozi od 66 mg (2 kapsule od 33 mg) i karbidope/levodope u dozi od 25 mg/100 mg u obliku tablete s trenutnim oslobađanjem procijenjena je u 24 zdrava dobrovoljca koji su u stanju natašte primali ukupno 50 mg karbidope svakih 8 sati.
Step 10: Remove capsule from inhaler Twist and pull off the mouthpiece 
10. korak: Izvadite kapsulu iz inhalatora Zakrenite, povucite i odvojite usnik
Patients should be on a stable levodopa/dopa-decarboxylase inhibitor (e.g. carbidopa or benserazide) regimen before starting Inbrija. 
Prije početka primjene Inbrije bolesnici moraju biti na stabilnom režimu doziranja levodope / inhibitora dopa-dekarboksilaze (npr. karbidope ili benserazida).
Withdrawal-emergent hyperpyrexia and confusion 
Hiperpireksija i konfuzija nakon prekida terapije
- medicines for your Parkinson's disease called selective MAO inhibitors such as rasagiline, selegiline and safinamide, COMT inhibitors such as entacapone, tolcapone and opicapone, or anticholinergics such as orphenadrine and trihexyphenidyl; 
Obavijestite svog liječnika ili ljekarnika ako uzimate: - lijekove za liječenje Parkinsonove bolesti koji se nazivaju selektivni MAO inhibitori, poput razagilina, selegilina i safinamida, inhibitore KOMT-a poput entakapona, tolkapona i opikapona, ili antikolinergike poput orfenadrina i triheksifenidila - lijekove za liječenje psihičkih stanja uključujući shizofreniju poput benperidola, haloperidola,
COMT inhibitors 
Inhibitori KOMT-a
There is limited data regarding chronic effect of Inbrija in respiratory compromised patients. 
Podaci o kroničnim učincima Inbrije na bolesnike s kompromitiranom respiracijom su ograničeni.
- A complete dose is 2 capsules taken one right after the other. 
- Puna doza iznosi 2 kapsule primijenjene jedna iza druge.
• Make sure your hands are clean and dry when using the inhaler and capsules. 
• Kada koristite inhalator i kapsule, pazite da Vam ruke budu čiste i suhe.
The change from baseline for DLCO was compared between the Inbrija treatment group and the observational cohort; at the end of 12 months, there was no significant difference in the change from baseline between Inbrija group and the observational cohort in DLCO. 
Promjene u odnosu na početne vrijednosti za DLCO uspoređene su između skupine liječene Inbrijom i opservacijske skupine na kraju razdoblja od 12 mjeseci; nije bilo značajne razlike u promjeni DLCO u odnosu na početne vrijednosti između skupine koja je primala
Worsening of Parkinson's disease, 
Trajanje Parkinsonove bolesti
It is recommended to administer this medicinal product cautiously to patients with severe hepatic impairment (see section 4.2). 
Preporučuje se lijek primjenjivati s oprezom u bolesnika s teškom bolešću bubrega (vidjeti dio 4.2).
Palpitations 
palpitacije
Inbrija is a medicine used by inhalation for treating the worsening of your symptoms during the “off periods” of Parkinson's disease. 
Inbrija je lijek koji se primjenjuje inhaliranjem za liječenje pogoršanja simptoma tijekom tzv. „off razdoblja“ kod Parkinsonove bolesti (razdoblja zakočenosti i nepokretnosti).
Care should be exercised when Inbrija is administered to patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias. 
Potreban je oprez kada se Inbrija primjenjuje u bolesnika koji u anamnezi imaju infarkt miokarda s posljedičnim atrijalnim, nodalnim ili ventrikularnim aritmijama.
- Two capsules of medicine should be inhaled to get the full dose. 
- Da bi se uzela puna doza lijeka, moraju se inhalirati dvije kapsule lijeka.
Cases of falsely diagnosed pheochromocytoma in patients on levodopa/dopa-decarboxylase inhibitor therapy have been reported very rarely. 
Slučajevi krive dijagnoze feokromocitoma u bolesnika koji primaju terapiju levodopom / inhibitorom dopa-dekarboksilaze zabilježeni su vrlo rijetko.
You may need to have tests on your heart, liver, kidney, and blood cell tests during long-term treatment with your medicines. 
Tijekom dugotrajnog uzimanja lijekova možda ćete trebati učiniti pretrage srca, jetre, bubrega i krvne slike.
Reduction in mean daily OFF time and improvement on the Patient Global Impression of Change (PGI-C) scale, a patient reported outcome of the overall improvement and satisfaction with Inbrija treatment, and Responders ON were the main secondary endpoints. 
Patient Global Impression of Change scale, PGI-C scale), sveukupno poboljšanje i zadovoljstvo liječenjem Inbrijom prema navodu samog bolesnika i bolesnici s ON odgovorom.
How to use Inbrija 
Kako uzimati Inbriju
Interference with test 
Interferencija s laboratorijskim pretragama
Do not swallow capsules. 
Ne gutati kapsule.
Take the inhaler out of your mouth and hold your breath for 5 seconds. 
Odmaknite inhalator od usta i zadržite dah
The active substance in Inbrija is levodopa. 
Djelatna tvar Inbrije je levodopa.
• A complete dose is 2 capsules used one after the other. 
• Puna doza iznosi 2 kapsule primijenjene jedna iza druge.
92 hard capsules + 1 inhaler 
60 tvrdih kapsula + 1 inhalator 92 tvrde kapsule + 1 inhalator
In the presence of carbidopa, the apparent terminal elimination half-life (t1/2) of levodopa following a single administration of Inbrija 66 mg (2 x 33 mg capsules) was 2.3 hours and comparable to that following an oral dose of carbidopa/levodopa 25 mg/100 mg immediate release tablets of 1.9 hours. 
U prisutnosti karbidope prividno terminalno poluvrijeme eliminacije (t1/2) levodope nakon jedne primjene Inbrije u dozi do 66 mg (2 kapsule od 33 mg) iznosilo je 2,3 sata i može se usporediti s onime nakon peroralne primjene karbidope/levodope u dozi od 25 mg/100 mg u obliku tablete s trenutnim oslobađanjem koje je iznosilo 1,9 sati.
If you have any of these symptoms, you may have a eye condition called narrow angle glaucoma, which occurs suddenly: do not take 
Ako su prisutni neki od tih simptoma, možda imate očnu bolest koja se naziva glaukom uskog kuta i nastupa iznenada, nemojte uzeti Inbriju i hitno potražite medicinsku pomoć.
Inbrija 33 mg inhalation powder, hard capsules 
Inbrija 33 mg prašak inhalata, tvrde kapsule
Concurrent administration of levodopa and amantadine may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. 
Istodobna primjena levodope i amantadina može pojačati konfuziju, halucinacije, noćne more,
Glaucoma 
Glaukom
Do not swallow Inbrija capsules. 
Ne gutati kapsule Inbrija.
Syncope, 
sinkopa,
Black iron oxide (E 172) Propylene glycol Potassium hydroxide 
Tinta šelak crni željezov oksid (E 172)
Breathe out completely. 
Izdahnite do kraja.
Pulmonary safety 
Sigurnost primjene za pluća
Paraesthesia, 
parestezija,
Fall a Cardiac rhythm disorder here is a combined term representing atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block, sick sinus syndrome, bradycardia, and tachycardia. 
atrioventrikularni blok, blok grane snopa, sindrom bolesnog sinusa, bradikardiju i tahikardiju.
Subjects had to be able to recognise OFF periods and to handle the device. 
Ispitanici su morali biti sposobni prepoznati OFF-razdoblja i rukovati inhalatorom.
Tear off package of 2 capsules. 
Odvojite dio blistera s 2 kapsule.
Nervous system disorders 
Poremećaji živčanog sustava diskinezija distonija,
• Only remove the capsules from the blister immediately before use. 
• Kapsule izvadite iz blistera samo neposredno prije primjene.
Gastrointestinal haemorrhage, Peptic ulcer (see section 4.4), Dysphagia, 
peptički ulkus (vidjeti dio 4.4), disfagija,
Inbrija 33 mg inhalation powder, hard capsules levodopa 
Inbrija 33 mg prašak inhalata, tvrde kapsule levodopa
Twist and pull off the mouthpiece. 
Zakrenite, povucite i odvojite usnik.
Step 6: Attach white mouthpiece Align arrows on mouthpiece and handle 
6. korak: Pričvrstite natrag bijeli usnik Poravnajte strelice na usniku i dršku
Levodopa may have a major influence on the ability to drive and use machines. 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Levodopa može značajno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
This punctures the capsule. 
Tako je kapsula probušena.
It is recommended to administer this medicinal product cautiously to patients with severe hepatic impairment. 
Preporučuje se lijek primjenjivati s oprezom u bolesnika s teškom bolešću bubrega.
Patients may experience new or worsening mental status and behavioural changes, which may be severe, including psychotic-like and suicidal behaviour during levodopa treatment or after starting or increasing the dose of levodopa. 
Mentalni poremećaji Tijekom liječenja levodopom, nakon započinjanja liječenja ili nakon povećanja doze levodope, u bolesnika mogu nastupiti promjene ili pogoršanje mentalnog stanja i promjene ponašanja, koje mogu biti teškog oblika, uključujući poremećaje nalik psihozi ili suicidalno ponašanje.
The capsules must only be removed from the blister immediately before use. 
Kapsule se iz blistera smiju izvaditi samo neposredno prije primjene.
Periodic skin examinations are recommended to monitor for melanoma in patients receiving Inbrija. 
U bolesnika koji primjenjuju Inbriju preporučuju se periodični pregledi kože zbog moguće pojave melanoma.
Parts of your Inbrija inhaler 
Dijelovi Inbrija inhalatora Strelice za poravnavanje
These may be symptoms of “withdrawal-emergent hyperpyrexia”. 
To mogu biti simptomi nastupa hiperpireksije zbog ustezanja primjene lijeka.
• Dispose of all used capsules immediately after use. 
• Nakon primjene iskorištene kapsule odmah bacite.
Symptomatic postural hypotension has occurred when combinations of levodopa and a dopadecarboxylase inhibitor are added to the treatment of patients already receiving certain antihypertensives. 
Simptomatska posturalna hipotenzija nastupila je kada su bolesnicima koji su primali određene antihipertenzive u terapiju dodane kombinacije levodope i inhibitora dopa-dekarboksilaze.
Dyspnoea, 
diplopija,
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva angioedem,
How to store Inbrija 
Kako primjenjivati Inbriju
Subject features 
Karakteristike ispitanika
Baseline Levodopa dose 
Početna doza levodope
Step 4: Remove 1 capsule from package 
4. korak: Izvadite 1 kapsulu iz pakiranja Pažljivo odvojite foliju i izvadite 1 kapsulu
Musculoskeletal and connective tissue disorders 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva mišićni spazmi, trizmus
The effect of Inbrija on pulmonary function was also evaluated in patients with Parkinson's disease treated with an oral levodopa/dopa-decarboxylase inhibitor in a 12-month, randomised, controlled, open-labeled study. 
Učinak Inbrije na plućnu funkciju procijenjen je i u bolesnika s Parkinsonovom bolesti liječenih primjenom peroralne levodope / inhibitora dopa-dekarboksilaze tijekom randomiziranog,
- The capsules must only be removed from the blister pack immediately before use. 
- Kapsule se iz blistera smiju izvaditi samo neposredno prije primjene.
- inability to resist the impulse to perform an action that could be harmful, which may include: - strong impulse to gamble excessively despite serious personal or family consequences; - altersed or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive; - uncontrollable excessive shopping or spending; - binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger). 
- prejedanje (uzimanje velikih količina hrane u kratkom vremenskom razdoblju) ili kompulzivno uzimanje hrane (uzimanje hrane u količini većoj nego što je uobičajeno i više od količine koja zadovoljava glad).
Hold the inhaler upright using the handle. 
Držite inhalator uspravno držeći ga za držak.
Anticholinergics 
Antikolinergici
Release the mouthpiece. 
Otpustite usnik.
Neoplasm benign, malignant and unspecified (incl. 
Dobroćudne, zloćudne i nespecificirane novotvorine
Adverse reactions are presented by system organ class and frequency in Table 1 below. 
U tablici 1 u nastavku prikazane su nuspojave prema klasifikaciji organskih sustava i prema učestalosti.
The primary efficacy endpoint was the mean change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) part III score 30 minutes post dose at week 12. 
Primarna mjera ishoda za djelotvornost bila je srednja vrijednost promjene od početnih vrijednosti, prema dijelu III Jedinstvene ocjenske ljestvice za Parkinsonovu bolest (engl.
You can use a dry cotton swab or tissue to wipe the outside of the inhaler. 
Možete ga obrisati izvana suhom pamučnom vaticom ili maramicom.
Restless legs syndrome, Neuroleptic malignant syndrome (see section 4.4), Ataxia, 
maligni neuroleptički sindrom (vidjeti dio 4.4),
Compress mouthpiece only once 
Pritisnite usnik samo jedanput
Responders ONb n = 97a n = 97a 
Ispitanici s ON odgovoromb n = 97a n = 97a
Coombs test positive, White blood cells urine positive, 
povišena vrijednost ureje u krvi, povišena vrijednost alkalne fosfataze u krvi, pozitivni Coombsov test, pozitivni nalaz leukocita u urinu,
Step 2: Remove blue cap from inhaler 
2. korak: Skinite plavu kapicu s inhalatora Ravno povucite kapicu.
The Inbrija inhaler is to be thrown away after all the capsules have been used. 
Nakon što se sve kapsule iskoriste Inbrija inhalator mora se baciti.
Step 7: Hold inhaler away and breathe out Stand or sit with your head and chest upright. 
Stojte ili sjednite s uspravnom glavom i prsnim košem.
- if you are taking certain antidepressant medicines called non-selective MAO inhibitors (e.g. 
- ako imate rijetki oblik tumora nadbubrežne žlijezde koji se naziva feokromocitom. - ako uzimate određene lijekove protiv depresije koji se nazivaju neselektivni MAO inhibitori (npr. izokarboksazid i fenelzin).
Suicide attempt (see section 4.4), Disorientation, Dopamine dysregulation syndrome, 
agitacija, pokušaj samoubojstva (vidjeti dio 4.4), dezorijentacija,
- Co-administration with non-selective monoamine oxidase (MAO) inhibitors. 
Neselektivni inhibitori monoaminooksidaze (MAO)
- melanoma (a type of skin cancer) or suspicious skin growths or marks. 
- novi ili pojačani neprirodni pokreti tijela (diskinezija) - osjećaj omaglice pri ustajanju (niski krvni tlak) - melanom (vrsta raka kože) ili sumnjive izrasline ili promjene na koži.
Depression, 
halucinacije, depresija,
Capsule content 
4 kapsule.
Orthostatic hypotension (see section 4.4), 
Krvožilni poremećaji ortostatska hipotenzija (vidjeti dio 4.4), hipertenzija,
See section 4.4 regarding withdrawal emergent hyperpyrexia and confusion. 
O nastupu hiperpireksije i konfuzije nakon prekida uzimanja levodope vidjeti u dijelu 4.4.
Make sure there are no capsules in the inhaler before you store it. 
Provjerite da u inhalatoru nema kapsula
• Dispose of the inhaler after you are finished all of the capsules in the carton. 
• Nakon što ste potrošili sve kapsule iz kutije, inhalator bacite.
Respiration abnormal, Dysphonia, Hiccups 
iritacija ždrijela dispneja, abnormalno disanje,
Capsule shell 
Plava kapica
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari Sadržaj kapsule kolfoscerilpalmitat (DPPC)
Inbrija may cause dyskinesia. 
Inbrija može uzorkovati diskineziju.
Baseline mean (SD) LS mean change Mean diff. (95% CI) p-value 
Srednja vrijednost razlike (95% CI)
Each carton includes blisters of 4 capsules. 
Kapsule Svaka kutija sadrži blistere s po
Confusional state, Hallucination, 
Psihijatrijski poremećaji stanje konfuzije,
Inbrija and get urgent medical attention. 
Inbriju i opservacijske skupine.
Step 8: Breathe in deeply to inhale powder While keeping the inhaler level, close your lips firmly around the mouthpiece. 
Držeći inhalator u razini usta, čvrsto stisnite usne oko usnika.
Step 13: Store inhaler Make sure there are no capsules in the inhaler 
13. korak: Čuvanje inhalatora
The median time to maximal plasma concentration of levodopa was 30 minutes after a dose of Inbrija 66 mg (2 x 33 mg capsules) compared to 45 minutes after a dose of carbidopa/levodopa 25 mg/100 mg immediate release tablets. 
Inbrije od 66 mg (2 kapsule od 33 mg) u usporedbi s 45 minuta nakon primjene karbidope/levodope u dozi 25 mg/100 mg u obliku tablete s trenutnim oslobađanjem.
On and off phenomenon, Somnolence, 
ON- i OFF-fenomen,